• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

121
16
12
10
9

COUNTRY

4
4
3
3
2

PRICE

91
121
261
409

PUBLISHED

7
10
89
409

PRODUCT TYPE

404
4
1

Immune Disorders

More than 150 primary immunodeficiency diseases (PIDs) have been identified, a number that does not include acquired immunodeficiencies. Examples of immune disorders include Type 1 diabetes, rheumatoid arthritis, allergies, Crohn’s Disease, and HIV, which infects over 0.5% of the world’s population.

In the reports and subscriptions listed under Research and Markets’ category you will find pipeline assessments of drugs and therapeutics, market forecasts, investment and growth opportunities, and much more. Also explored in-depth is the key role of immune response and pharmaceuticals in transplant medicine, with reviews of clinical trials, market trends and major companies in the areas of lung transplants, liver transplants, transplant inflammation/rejection, etc.

Key players profiled include Abbott Laboratories, Pfizer, Johnson & Johnson, Biogen Idec, Amgen, Bayer AG, Sanofi, and more. Show Less
Read more

PRODUCT TITLE

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Current and Future Players

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis...

October 2013
FROM

Tabalumab (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Tabalumab (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

Orencia (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Orencia (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Germany Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

Lupuzor (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Lupuzor (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 Summary The lupus therapeutics market is dominated by generics and GlaxoSmithKline’s...

October 2013
FROM

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2013

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2013', provides an overview of the indication’s...

October 2013
FROM

House Dust Mite Allergy - Pipeline Review, H2 2013

House Dust Mite Allergy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'House Dust Mite Allergy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Chronic Plaque Psoriasis - Pipeline Review, H2 2013

Chronic Plaque Psoriasis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Chronic Plaque Psoriasis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Chronic Plaque Psoriasis Global Clinical Trials Review, H2, 2013

Chronic Plaque Psoriasis Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Chronic Plaque Psoriasis Global Clinical Trials Review, H2, 2013" provides data on the Chronic...

October 2013
FROM
Therapy Class Overview : Hepatitis C Virus Infection Therapy Class Overview : Hepatitis C Virus Infection - Product Thumbnail Image

Therapy Class Overview : Hepatitis C Virus Infection

Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future This year the first IFN-free...

October 2013
FROM

Heart Transplantation Global Clinical Trials Review, H2, 2013

Heart Transplantation Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Heart Transplantation Global Clinical Trials Review, H2, 2013" provides data on the Heart Transplantation...

September 2013
FROM

Inflammation Global Clinical Trials Review, H2, 2013

Inflammation Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Inflammation Global Clinical Trials Review, H2, 2013" provides data on the Inflammation clinical trial scenario....

September 2013
FROM

Myasthenia Gravis Global Clinical Trials Review, H2, 2013

Myasthenia Gravis Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Myasthenia Gravis Global Clinical Trials Review, H2, 2013" provides data on the Myasthenia Gravis clinical...

September 2013
FROM

Cat Allergy - Pipeline Review, H2 2013

Cat Allergy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Cat Allergy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

September 2013
FROM

Lupus Erythematosus - Pipeline Review, H2 2013

Lupus Erythematosus - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Lupus Erythematosus - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

September 2013
FROM

Lupus Nephritis - Pipeline Review, H2 2013

Lupus Nephritis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Lupus Nephritis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

September 2013
FROM

Kidney Transplantation - Pipeline Review, H2 2013

Kidney Transplantation - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Kidney Transplantation - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

September 2013
FROM

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2013

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2013', provides an overview of the indication’s...

September 2013
FROM

Moderate Psoriasis - Pipeline Review, H2 2013

Moderate Psoriasis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Moderate Psoriasis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

September 2013
FROM
Loading Indicator

Our Clients

Our clients' logos